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Abstract
There is a high prevalence rate (30-50%) of Alzheimer’s disease (AD) and depression comorbidity. Depression can
be a risk factor for the development of AD or it can be developed secondary to the neurodegenerative process.
There are numerous documented diagnosis and treatment challenges for the patients who suffer comorbidity
between these two diseases. Meta analysis studies have provided evidence for the safety and efficacy of antide-
pressants in treatment of depression in AD patients. Preclinical and clinical studies show the positive role of
chronic administration of selective serotonin reuptake inhibitor (SSRI) antidepressants in hindering the progression
of the AD and improving patient performance. A number of clinical studies suggest a beneficial role of combina-
torial therapies that pair antidepressants with FDA approved AD drugs. Preclinical studies also demonstrate a favor-
able effect of natural antidepressants for AD patients. Based on the preclinical studies there are a number of
plausible antidepressants effects that may modulate the progression of AD. These effects include an increase in
neurogenesis, improvement in learning and memory, elevation in the levels of neurotrophic factors and pCREB and
a reduction of amyloid peptide burden. Based on this preclinical and clinical evidence, antidepressants represent a
rational complimentary strategy for the treatment of AD patients with depression comorbidity.
1. Classes of antidepressants
The monoamine hypothesis postulates that depletion in
the levels of serotonin, norepinephrine, and/or dopa-
mine in the central nervous system are the pathophysio-
logic basis of depression. There are five major classes of
antidepressants that are categorized according to their
mechanism of action on brain amines.
1.1 Non selective monoamine reuptake inhibitors (NSRI)
The nonselective monoamine reuptake inhibitor (NSRI)
class of antidepressants includes the tricyclic antidepres-
sants (TCA), a group of antidepressants introduced in
the 1950s that inhibit the reuptake of both serotonin
and noradrenalin. Examples of this class are imipramine,
clomipramine, amitriptylinea n dd e s p i r a m i n e( F i g .1 A )
[1]. Some reports suggest that dual inhibitors may have
superior efficacy and earlier response than selective
reuptake inhibitors for a single monoamine [2,3]. In
terms of the chemical structure, some TCAs, such as
imipramine and amitriptyl i n e ,h a v eat e r t i a r ya m i n e
structure and are metabolized to secondary amines
(Fig. 1A). Other TCAs, such as despiramine and nortrip-
tyline, are secondary amines (Fig. 1A)[4]. In addition to
their therapeutic effects; TCAs also have a number of
unwanted side effects including antihistaminic, cardio-
toxic and anticholinergic effects. These side effects are
due to the action of TCAs on adrenergic receptors (a1),
Na
+,C a
2+ cardiac channels, histamine (H1) and mus-
carinic receptors [5-7]. The prescription of TCAs has
declined due to these unwanted side effects and the
advantage of new antidepressants with a better tolerabil-
ity profile [4].
There are other non-selective monoamine inhibitors
that are structurally different from TCAs but share a
similar mechanism of action. Examples of these agents
are venlafaxine, duloxetine and milnacipran. Venalafaxine
is a derivative of bicyclic phenethylamine and is a more
potent inhibitor of serotonin reuptake than norepinephr-
ine reuptake, in addition to low dopamine reuptake inhi-
bition [6,8]. Milnacipran inhibits the reuptake of
serotonin and norepinephrine with a similar potency and
a negligible effect on dopamine reuptake (Fig. 1A) [9].
Clinical trials of duloxetine in the United States have
demonstrated its efficacy in major depressive disorders,
particularly those associated with physical pain [10,11].
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The selective norepinephrine reuptake inhibitor (SNRI)
class of antidepressants selectively inhibits the reuptake
of noradrenaline. Examples of this class are maprotiline
and reboxetine (Fig. 1B) [1]. Maprotiline causes side
effects similar to those of TCAs including dry mouth,
fatigue and weight gain. Reboxetine formulations typi-
cally consist of a racemic mixture where the (S)
enantiomer is 20 times more potent than the (R) enan-
tiomer [12,13]. The primary unwanted side effects of
reboxetine are cardiovascular and urinary effects.
1.3 Selective serotonin reuptake inhibitors (SSRI)
The selective serotonin reuptake inhibitor (SSRI) class
includes antidepressants that selectively inhibit the reup-
take of serotonin and subsequently increase the amount of
Figure 1 A: Represents examples of non-selective monoamine reuptake inhibitor (NSRI) antidepressants.B :R e p r e s e n t se x a m p l e so f
selective nor epinephrine reuptake inhibitor (SNRI) antidepressants. C: Represents examples of selective serotonin reuptake inhibitor (SSRI)
antidepressants. D: Represents examples of Monoamine oxidase inhibitor (MAOI) antidepressants. E: Represents examples of atypical
antidepressants. All the structures are downloaded from PubChem Substance http://pubchem.ncbi.nlm.nih.gov/.
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SSRIs are the most commonly prescribed class of antide-
pressants. Examples of this class are citalopram, sertaline,
fluvoxamine, fluoxetine and paroxetine (Fig. 1C) [1].
Though these compounds have different pharmacokinetic
profiles and chemical structures, they are all metabolized
primarily by oxidation prior to excretion [14]. In terms of
chemical structure (Fig. 2), fluoxetine has a side chain of
propylamine similar to TCAs while citalopram has a
dimethyl aminopropyl side chain (Fig. 1C). Paroxetine, ser-
traline and fluvoxamine are derived from phenylpiperidine,
tetrahydronaphthalene and arylketone respectively (Fig.
1C). The major advantage of the introduction of SSRIs in
the 1980s was their good safety and tolerability profiles.
These favorable profiles are attributed to the low affinity
of SSRIs to histamine, muscarinic and a adrenergic recep-
tors. Although SSRIs have a good safety profile, it is
important to note probable drug-drug interactions due to
an inhibitory effect by some SSRIs on the P450/2D6 cyto-
chrome enzyme [15]. Additionally, reports show that
SSRIs have a similar effect as TCAs on K
+,C a
2+ and Na
+
cardiovascular channels, which may contribute to the car-
diovascular effects reported in some patients [7,15,16].
Also, sexual dysfunction is a significant side effect that has
been reported for SSRIs [17].
1.4 Monoamine oxidase inhibitors (MAOI)
The monoamine oxidase inhibitor (MAOI) class of anti-
depressants inhibits monoamine oxidase (MAO), the
enzyme responsible for the metabolism of monoamines.
An example of this class is tranylcypromine (Fig. 1D) [1].
Tranylcypromine irreversibly and nonselectively binds to
MAO-A and MAO-B. There is a high tendency for
hypertensive crisis associated with the use of irreversible
and nonselective MAOIs with the concomitant ingestion
of tyramine [4]. The development of selective and rever-
sible inhibitors of MAO-A has provided a better safety
profile [4]. MAO-A metabolizes the amines that play a
major role in depression etiology. Examples of new
agents selective for MAO-A are cimoxatone and moclo-
bemide, derived from benzonitrile and benzamide respec-
tively (Fig. 1D). Due to dangerous dietary and drug
interactions, the use of MAOIs is generally reserved for
patients who don’t respond well to other antidepressants
or suffer from atypical depression [18,19].
1.5 Atypical antidepressants
Atypical antidepressant agents produce an antidepres-
sant effect, but their mechanism of action is not based
on the monoamine hypothesis. Examples of this class
are bupropion, tianeptine and mirtazapine (Fig. 1E).
These compounds have well characterized mechanisms
of action, but these mechanisms may not necessarily
account for the antidepressant effects [1]. Bupropion
inhibits the reuptake of dopamine, tianeptine stimulates
the uptake of monoamines, and mirtazapine antagonizes
a2 adrenergic receptors [1].
There are also many other classes of antidepressants
that have been developed recently that are beyond the
scope of this review. These drugs have different targets
such as the dopaminergic system, serotonin receptors,
adrenergic receptors and neuropeptide receptors (for
review see [4]).
2. Depression and Alzheimer’s disease
comorbidity
Substantial evidence suggests that depression can be con-
sidered both a cause and consequence of a number of
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Figure 2 Summary of different actions of antidepressants that can modulate the pathological features of Alzheimer’s disease.
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disorders has not been determined yet [20]. Depression is
considered causative because it is a risk factor for AD [21]
particularly if a depressive episode is evident within two
years of a dementia diagnosis. In such cases, the depressive
episode is considered an early symptom of dementia
[22-24]. Depressive symptoms are commonly detected
before AD patients manifest cognitive deterioration or are
clinically diagnosed [25-27]. Depression instigates a num-
ber of complications for AD patients including an increase
in mortality, compromise of cognitive function [28] and
hindrance in daily living activities [29].
The prevalence rate of depression and AD comorbid-
ity is estimated to be 30-50% [30]. The comorbidity
between these two diseases is heterogeneous and is con-
sequently divided into more descriptive subtypes [30].
This categorization takes into consideration the fact that
depression can be a risk factor for the development of
AD [31] or it can be secondary to the neurodegenerative
process [32]. Several pathological events have been dis-
covered that provide a mechanistic link between these
two diseases. Comorbidity may be due to depletion of
the central superior raphe nucleus [33] or locus coeru-
leus neurons [34]. Additionally, high levels of glucocorti-
coids are secreted during depressive episodes that may
later have dramatic effects on the hippocampus and lead
to dementia symptoms [35].
There are also factors identified that increase the risk
of depression development in AD patients. These factors
include AD onset at a young age, a family history of
mood disorders or depressive symptoms, and female sex
[36]. Strong evidence suggests that depressive episodes
can be a predictive measure for cognition loss among
elderly people who suffer from moderate cognitive
impairment [28].
The comorbidity between these diseases poses an
impact not only on the patient but also on the caregiver
who may suffer higher levels of stress due to the distur-
bances in the behavior of patients as a result of depres-
sion [37]. Caregiver depression is related to patient
depression, a consequence that leads to hindrance in the
delivery of adequate patient care [38]. It is possible to
alleviate the depressive symptoms in both the patient
and caregiver groups using certain behavioral interven-
tions that target the patient and involve caregiver parti-
cipation [39].
A clinical study on the homebound elderly reported
that elderly who are non-ApoE4 allele carriers with
depression symptoms exhibit lower levels of Ab 42 and
consequently higher plasma ratio of Ab40/Ab42 in com-
parison to non-ApoE4 carriers without depressive symp-
toms. Because a high Ab40/Ab42 ratio is considered to
be a risk factor for AD, depression is thought to be a
risk factor in the absence of ApoE4 [40]. Another study
of geriatric depression reported preliminary findings of
high levels of Ab42 and a high ratio of Ab42/Ab40 in
patients with late onset depression [41,42]. The exact
relationship between declines in cognitive function and
plasma levels of amyloid peptide remains to be deter-
mined in patients who suffer from AD and depression
comorbidity.
2.1 Diagnosis challenges
Diagnosis of depression itself is challenging due to the
absence of objective diagnostic tests. There is a shortage
in the available knowledge of the neuronal circuitry that
is involved in depression, and it is unclear where a
biopsy should be taken from depressed patients. The
heterogeneity of depression adds to the complexity of
t h ed i a g n o s i sa sw e l ls i n c em u l t i p l eb r a i nr e g i o n sa r e
likely to be involved [1].
Diagnosing depression associated with neurological
disorders poses further challenges. These diseases fre-
quently have overlapping symptoms and exhibit a simi-
lar etiology. Aphasia is an example of an overlapping
symptom, which interferes with the patient and physi-
cian’s ability to communicate regarding the emotional
state [43]. Additionally, a reduction in the levels of neu-
rotransmitters such as serotonin and norepinephrine is
a similar etiology between AD and depression [44-47].
There is an urgent need for standardized protocols for
the diagnosis of depression associated with AD [30].
This need is reflected by an ongoing effort by the
National Institute of Mental Health (NIMH) to develop
a standard protocol for the diagnosis of depression in
AD [48].
2.2 Treatment challenges
One of the major treatment challenges is the lack of a
clear treatment guide in these patients. The research
methodology and the diagnostic criteria heterogeneity
confound the clinical results. Another challenge is the
strong placebo effect recorded for antidepressant treat-
ment as seen in clinical trials with the TCAs clomipra-
mine [4] and imipramine [49]. The major treatment
goal for depression comorbid with other neurological
disorders is to relieve the depressive symptoms and
improve the coping resources for the neurologic disor-
der. Research that addresses the depression comorbidity
with AD will lead to better treatment outcomes and
may also lead to a better understanding of the neuroa-
natomy of depression [43].
3. Preclinical studies on mechanisms of the
antidepressants in relation to Alzheimer’s disease
3.1 Antidepressants stimulate neurogenesis
Recently several groups have demonstrated that neuro-
genesis exists in the adult brain mainly in two regions.
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subgranular zone (SGZ) of the dentate gyrus in the hip-
pocampus, an area of the brain that is known to have
an important role in learning and memory [50-53].
Reduction in neurogenesis in the SGZ is related to
impairment of cognition associated with the aging pro-
cess and AD, and it may greatly affect the progression
of AD [50,54]. Reduction in neurogenesis is implicated
in the early symptoms of AD such as impairments in
acquiring information and eventually storing it [55].
This is particularly evident in some AD animal models
such as mice with the APP and presenilin mutations,
which have impairment in dentate gyrus neurogenesis
[56-61]. This impairment has led to the introduction of
endogenous neuronal precursors as a therapeutic strat-
egy for AD [61-66]. The triple transgenic (3×Tg-AD)
AD mouse model that carries mutations in the amyloid
precursor protein (APPswe), taup301L and presenilin
1PS1M146V exhibits amyloid peptide and tau pathology
resembling the human AD brain [67,68]. The triple
transgenic (3×Tg-AD) mouse model exhibits an age
dependent reduction in adult neurogenesis. At 9 months
of age, male 3×Tg-AD mice have approximately a 73%
reduction in the generation of new neurons; after 12
months neurogenesis is completely diminished. The
reduction in neurogenesis has been correlated to the
existence of amyloid peptide plaques and elevation in
the number of hippocampal neurons containing amyloid
peptide [69]. This study highlights the importance of
early intervention to rescue neurogenesis in AD patients,
which may then delay the progression of cognitive
impairment. There are new strategies to replenish neu-
ronal loss in AD by stimulating endogenous neurogen-
esis and transplanting neuronal progenitors (NP) [70].
Depression and stress may also decrease neurogenesis
and chronic treatment with antidepressants can antago-
nize this effect and increase neurogenesis in the hippo-
campus [64,71]. Interestingly, the effects of
antidepressants on neurogenesis are evident across dif-
ferent classes including the SNRIs, SSRIs, MAOIs and
atypical antidepressants. This neurogenic effect requires
chronic administration between 14-21 days, and includes
an increase in the proliferation rate and new neuron
survival [72]. The underlying mechanisms that mediate
the neurogenic effects of antidepressants have not been
identified, but there is strong evidence that neurotrophic
factors such as fibroblast growth factor-2, insulin-like
growth factor-1 (IGF-1) and brain derived neurotrophic
factor (BDNF) are important for this effect [4]. It has
been reported that the increase in the new neuron survi-
val rate but not the proliferation rate is dependent on
BDNF [73]. Antidepressant activation of the CREB path-
way has also been implicated as an important compo-
nent underlying the neurogenic effect [74]. Fluoxetine
(SSRI) treatment for as short as 5 days can increase
synaptic density in the hippocampus as determined by
electron microscope [75]. In contrast, amitriptyline
(TCA) treatment does not increase the number of
synapses but reduces declines in synaptic density as a
result of olfactory bulbectomy, a well established animal
model for depression [76]. Chronic tiapentine (atypical
antidepressant) treatment prevents reduction of dendrite
length as a result of chronic stress [77]. Behavioral stu-
dies imply that the neurogenic effect of antidepressants
is required to mediate antidepressant action. In a study
by Santarelli et al., cell proliferation was inhibited by
irradiation and subsequently blocked antidepressant
action in chronic unpredictable stress and novelty sup-
pressed feeding [78]. Chronic unpredictable stress and
novelty suppressed feeding are depression animal mod-
els that require long term treatment with antidepres-
sants to produce antidepressant action and are
particularly relevant when the role of the neurogenesis
is investigated [79]. In contrast, the tail suspension and
forced swim tests require acute administration of antide-
pressants to produce antidepressant action. Chronic
administration of antidepressants corresponds to the
time frame that is required for the maturation and dif-
ferentiation of new neurons to functional ones [80].
It is important to mention that acute versus chronic
administration is considered a variability factor in the
forced swim test [81]. The forced swim testis utilized to
screen for acute antidepressant effects, although a
c h r o n i ct i m ec o u r s ei sr e q u i r e df o rt h ec l i n i c a le f f e c t s
[81]. A study addressing the effect of fluoxetine on the
forced swim test after different dose intervals demon-
strated that chronic administration can enhance the
effects seen at acute or subchronic dosing [82]. This
study calls attention to the weak face validity of the
forced swim test [81].
Based on these animal studies where a reduction in
neurogenesis was demonstrated to lead to cognitive
impairment and the ability of antidepressants to stimu-
late adult neurogenesis, antidepressant treatment may
provide AD patients with an advantage. Concurrent
antidepressant treatment may increase the proliferation
and survival of new neurons, particularly if the treat-
ment is started early when depressive symptoms appear
as a risk factor.
3.2 Antidepressants stimulate learning and memory
After 65 years of age, the elderly must cope with altera-
tions in memory as a part of the normal aging process.
This is evident in recognition memory changes [83] and
impairment of spatial memory [84,85]. Also, hippocampal
dysfunction may underlie alterations in memory during
the aging process, and has been consistently observed
across different species [83]. Given that age is an
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people over 65 years suffer from AD [86], drugs that sti-
mulate learning and memory carry important benefits to
AD patients. There are major changes in the hippocam-
pus associated with the aging process such as electrophy-
siological silence in synapses as a result of reduction in
the post synaptic density, difficulty in encoding and
retaining information as evident by reduction in long
term potentiation (LTP) and elevation in long term
depression (LTD) and synaptic contact loss [87]. The
main endophenotype of major depression is impairment
in cognition [88]. This is clinically evident by difficulty in
concentration and attention due to abnormalities and
neuropathological changes in dorsolateral prefrontal cor-
tex that is critical to these capacities [89-91]. Interest-
ingly, preclinical studies in animals report that chronic
treatment with antidepressants increase LTP and field
potential baseline in dentate gyrus in a similar way to
chronic electromagnetic stimulation [92,93]. It is specu-
lated that the increase in newborn granule cell number in
the dentate gyrus underlies the potential neuroplastic
effect [94,95]. On the other hand, earlier reports showed
that tricyclic antidepressants reduce LTP in CA1 pyrami-
dal cells [96,97]. The reduction of LTP can be attributed
to anticholenergic effects of the TCA that counteract
their effects on neuroplasticity [80]. As a proof of con-
cept, chronic treatment with atypical antidepressant (tia-
pentine) or SSRIs that have less anticholinergic
properties in comparison to TCAs increase LTP and pre-
vent stress induced reduction in LTP [98,99]. Another
report confirms the beneficial effects of chronic fluoxe-
tine and tiapentine treatment in preventing stress
induced reduction of LTP in hippocampus-prefrontal
cortex circuitry [100]. Based on these studies, it is evident
that chronic administration of SSRIs increases cellular
plasticity in dentate gyrus and CA1 pyramidal cells and
prevents the harmful effects of stress in hippocampal
neurons. Additionally, the anticholinergic properties of
TCAs may counteract their neuroplastic effects.
There are conflicting reports on how SSRI treatment
affects performance in the Morris water maze, a typical
model for spatial learning and memory. Reports demon-
strated an improvement in Morris water maze perfor-
mance after chronic treatment with venlafaxine or
fluoxetine [101-103]. Another study reports that fluoxe-
tine does not affect performance in the Morris water
maze [93]. Chronic treatment with the atypical antide-
pressant tiapentine does not affect performance in the
Morris water maze [102] but improves performance in
the radial maze discrimination task [104]. Chronic treat-
ment with the TCA amitriptyline blocked age induced
deterioration of learning and memory [105]. In contrast
to SSRIs and amytriptyline, imipramine does not affect
performance in the Morris water maze [101] and even
worsens spatial working memory in the radial arm maze
test [106]. The fact that TCAs impair cognitive function
has also been reported in some clinical trials [49,107].
These preclinical studies raise awareness about selection
of the proper antidepressant for AD patients. Based on
the reports that have shown some antidepressants can
cause memory impairment, close attention should be
paid to antidepressants prescribed to AD patient [108].
3.3 Antidepressants and N-methyl-D-aspartate (NMDA)
receptors
Mounting evidence supports the hypothesis that inade-
quate stimulation of NMDA receptors is a pathophysio-
logical component of both depression and AD. The
NMDA receptor represents an interesting treatment tar-
get due to the comorbidity between these two diseases
[109-112]. Under normal physiological conditions, the
synaptic activity of NMDA receptor modulates APP pro-
cessing towards a direction that favors non-amyloido-
genic a-secretase processing of amyloid precursor
protein [113]. APP processing by a-secretase is reduced
as a result of chronic NMDA receptor stimulation and
leads to an increase in amyloid peptide production in
the cortical neurons that resembles the pathophysiologi-
cal conditions of AD [114]. Stress induced hippocampal
neuronal atrophy and reduction in neurogenesis can be
blocked by NMDA receptor antagonist treatment [115].
A number of studies report that chronic antidepres-
sant treatment can modulate the expression of specific
NMDA receptors subunits and ultimately NMDA recep-
tor function [116-120]. NMDA receptor function is
reduced after treatment with antidepressants [121-123].
Tricyclic antidepressants inhibit the NMDA receptor
directly [124,125]. Milnacipran is a serotonin and nore-
pinephrine reuptake inhibitor that antagonizes the
NMDA receptor noncompetitively [126]. The SSRI
fluoxetine inhibits the NMDA receptor directly [127].
Additionally, NMDA receptor antagonists such as
memantine, 2-amino-7-phosphoheptanoic acid (AP-7),
eliprodil, 1-aminocyclopropancarboxylic acid (ACPC),
MK-801 and fenprodil have antidepressant-like effects
[128-130]. Memantine and MK-801 are noncompetitive
NMDA receptor antagonists, AP-7 is a competitive
NMDA receptor antagonist, ACPC is partial agonist on
the glycine site, and eliprodil and fenprodil work on the
polyamine binding site of the NMDA receptor
[128-130]. Interestingly, a case report for the antiviral
agent amantadine which has NMDA receptor antagonis-
tic activity provides clinical evidence for its efficacy in
depression [131]. Ketamine is another NMDA receptor
antagonist, which has antidepressant effects after a sin-
gle dose administration in depressed patients [132].
Ketamine also exhibits antidepressant and anxiolytic
effects in animal models of depression [133].
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patients who suffer from AD and depression. It can
treat the depressive symptoms in addition to targeting
NMDA receptor activity in AD patients. Of note is the
fact that inhibition of NMDA activity is evident in SSRI
agents such as fluoxetine, which have a better tolerabil-
ity profile in comparison to TCAs.
3.4 Antidepressants, serotonin, BDNF and pCREB
Serotonin signaling pathways are implicated in the
pathology of AD since the death of the neurons and the
dysfunction of the synapse can be a result of reduction
in the activation of serotonin coupled signaling path-
ways [134]. Amyloid peptide deposition, a major patho-
logical feature of AD, interferes with the
phosphorylation of cAMP-response element-binding
protein (CREB) [135]. Intracellular amyloid peptide load
affects this signaling pathway differently. Moderate ele-
vation in levels of intracellular amyloid peptide load
leads to over expression in CREB responsive genes such
as BDNF, presenilin 1 and presenilin 2. High levels of
intracellular amyloid peptide lead to persistent CREB
hyperphosphorylation and block its translocation to the
nucleus resulting in inhibition of cyclic AMP-response
(CRE) directed gene expression [136]. The authors spec-
ulate that inhibition of CREB translocation causes early
synaptic dysfunction prior to the extracellular accumula-
tion of amyloid peptide [136].
Chronic treatment with antidepressants increases the
synaptic concentrations of noradrenaline and/or seroto-
nin. These increased levels then lead to activation of G-
protein coupled receptors, stimulation of adenyl cyclase,
and eventually upregulation of the cAMP cascade. This
cascade results in increases of CREB and BDNF expres-
sion and increases in the levels of cAMP-dependent pro-
tein kinase (PKA) [4,115,137-139]. Serotonin
enhancement of synaptic plasticity is mediated by activa-
tion of CREB and increases in BDNF levels [140].
Given the high prevalence rate of comorbidity
between depression and AD, it is important to screen
AD animal models for depressive symptoms. R406 W
transgenic mice are an AD animal model with tau
hyperphosphorylation, deposition of neurofibrillary tan-
gles in forebrain and impairment in associative memory
[141,142]. Interestingly, R406 W transgenic mice have
been evaluated in the forced swim test and have been
demonstrated to exhibit a longer immobility time than
non-transgenic mice [141]. Fluvoxamine not desipra-
mine treatment of R406 W transgenic mice restores
immobility time in the forced swim test to wild type
levels. This study implies that R406 W transgenic mice
demonstrate depressive behaviors and provide evidence
for the involvement of serotonin in these depressive
symptoms. Indeed, these mice exhibited low levels of
5-hydroxyindoleaceticacid (5-HIAA) and serotonin, and
fluoxamine treatment restores serotonin levels compar-
ably to control group. This study raises speculations
that the R406W mutation affects serotonergic neurons
[141]. Postmortem AD brains show reductions in the
levels of serotonin and its metabolites [44,143], which
highlight the advantage of prescribing SSRIs to AD
patients versus other antidepressants.
There is an association between reduced levels of neu-
rotrophic factors and depressive symptoms, and mount-
ing evidence supports the hypothesis that part of
antidepressant action involves increasing levels of neuro-
trophic factors to compensate for their reduced levels in
depressed patients [144,145]. There is a family of structu-
rally related trophic factors that includes BDNF, neuro-
trophin-3, neurotrophin-4 and nerve growth factor
(NGF). Generally, the production of BDNF mRNA results
from the stimulation of 5-HT receptor and b-adrenocep-
tor coupled signaling pathways. The growth and function
of serotonergic neurons are greatly increased by BDNF
[145,146]. BDNF also reduces mRNA and protein levels
of NMDA receptor subunits and reduces NMDA stimu-
lated Ca
2+ increase [147]. BDNF and NGF specifically
have important effects on hippocampal neurons that are
involved in the pathogenesis and clinical features of AD
[66,148,149]. It has been reported that the amyloidogenic
pathway is activated as a result of NGF deprivation [150]
and that BDNF or NGF signaling interruption leads to
cell death and accumulation of Ab aggregates intracellu-
larly and extracellularly [151]. A recent study demon-
s t r a t e dt h a tB D N Fg e n ed e l i v ery significantly restored
learning and memory, reversed synaptic loss, partially
normalized inappropriate gene expression and improved
cell signaling in transgenic mice even after disease onset
[152]. Neurotrophic factors have now entered clinical
trials as both a preventative measure and as a treatment
to reduce neuronal loss and stimulate neurogenesis
[153,154]. These studies demonstrate that BDNF is likely
a key player in mediating the beneficial effects of antide-
pressants in AD patients.
3.5 Antidepressants and amyloid peptide
The effect of antidepressants on amyloid peptide has
particular importance. The high prevalence rate of
comorbidity between depression and AD warrants the
investigation of the possible dual role for antidepressants
in modulating these two diseases. Additionally, antide-
pressants activate similar signaling pathways as the ones
activated by dietary restriction and environmental
enrichment, both of which have been demonstrated to
reduce amyloid peptide burden in transgenic mice
[134,155,156].
Chronic treatment with paroxetine for 5 months in
3×TgAD mice significantly reduces the levels of amyloid
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[157]. Tau immunoreactivity is also significantly reduced
in the hippocampus and amygdala in paroxetine treated
mice [157]. Although the underlying mechanism for the
action of paroxetine in reducing amyloid peptide burden
and tau pathology is undetermined, there is speculation
that the effect is due to enhancement of serotonin sig-
naling and elevation of BDNF expression levels
[134,158]. To investigate whether the effect of antide-
pressants on amyloid peptide is limited to the SSRI
class, we examined the effect of increasing concentra-
tions of antidepressants on Ab expressing N2a neuro-
blastoma cells by Western blotting. The tested
antidepressants include the SSRIs fluoxetine and paroxe-
tine, the selective noradrenaline reuptake inhibitor
maprotiline and the nonselective monoamine reuptake
inhibitor imipramine. Interestingly, fluoxetine and par-
oxetine at 10 μM significantly decrease Ab oligomers,
but do not affect the levels of extracellular amyloid pep-
tide (unpublished data). Based on these results, fluoxe-
tine and paroxetine are likely to be beneficial to AD
patients due to their role in modulating Ab metabolism.
This effect may also explain some of the beneficial
effects of SSRIs in AD patients. In a screening assay for
small molecules that can interact with Ab fibrils, fluoxe-
tine does not show potential to interact with Ab fibrils
directly [159].
Targeting amyloid precursor protein (APP) gene
expression is a major anti-amyloid strategy in the treat-
ment of AD. Desferrioxamine and phenserine target the
5’ untranslated part of APP and ultimately inhibit APP
translation [160]. Interestingly, paroxetine was one of
the APP 5’UTR lead directed compounds based on a
screening study from a 1,200 compound library [161].
Paroxetine treatment for 48 hours in B3 lens epithelial
cells reduces the levels of Ab secreted into the medium
[161,162]. B3 lens epithelial cells were specifically used
in this study due to high baseline levels of amyloid pep-
tide [163]. TgCRND8 mice treated with paroxetine for
three months had reduced levels of Ab (1-40) and APP
levels in brain homogenate. TgCRND8 mice were
selected for this study because the APP gene open read-
ing frame is over expressed in these mice, providing a
p r o o fo fc o n c e p tf o rt h eA P P5 ’UTR targeting strategy
[163,164].
Another in vitro study addressed the effect of TCAs
and SSRIs on APP processing in rat primary basal fore-
brain cultures [165]. Imipramine at 100 μM significantly
reduced intracellular levels of APP after two hours of
treatment. Imipramine and citalopram significantly
increased the levels of secreted APP in the medium of
the treated primary cultures [165]. Interestingly, seroto-
nin and muscarinic agonists also increase APP secretion
[166-168]. It is anticipated that the increase in APP
secretion is accompanied by a decrease in intracellular
APP levels. Presumably, the secreted APP will not be
available for processing by b and g secretases [165].
Whether the effect of antidepressants on APP proces-
sing and amyloid peptide are a class effect or whether
these effects relate to pharmacological mechanisms indi-
vidual antidepressant agents has not been determined.
3.6. Natural antidepressants and AD (Ginkgo, St. John’s
wort, flavonoids, and curcumin)
St. John’sw o r t( Hypericum perforatum) extract (HPE) is
well known for its antidepressant effects [169-171].
Hyperforin is considered to be the major active consti-
tuent that contributes to the neuroprotective effect of
HPE [172]. The antidepressant action of hyperforin is
primarily attributed to monoamine reuptake inhibition
[173]. Other components in HPE have also been identi-
fied to have an important contribution to the antide-
pressant effect of HPE such as flavonoids [174],
pseudohypericin and hypericin [175].
HPE extract has been demonstrated to exhibit neuro-
protective properties by preventing the toxic effect of
amyloid peptide (25-35) in the hippocampal neurons of
the rat. HPE reduced lipid peroxidation, cell death and
dendritic lesions [176]. In another study, pretreatment
of a microglial cell line with HPE showed a dose depen-
dent reduction in amyloid peptide induced cell death
[177]. To study the effect of individual components of
HPE on cell viability, individual constituents of the HPE
mixture were incubated with the microglial cell line.
Some flavonols such as (-)-epicatechin and (+)-catechin
increased the viability of the cells but other flavonols
and glycosides such as quercitrin, quercetin, hyperosid
and rutin had no effect [177]. The antioxidant properties
of the flavonoids resulted in reduced reactive oxygen
species (ROS) production induced by amyloid peptide in
the microglia [177]. Hyperforin in particular has been
demonstrated to enhance memory in rodents [178].
Another study reported that hyperforin improved spatial
memory by reduction of reactive astrocytes, activation
of microglia and promotion of amyloid peptide deposit
fragmentation [179]. Hyperforin also protects cells
against the neurotoxic effect of amyloid peptide oligo-
mers and fibrils and reduces the production of ROS
[179]. An in vitro study demonstrated that hyperforin
promotes the dissociation of amyloid peptide deposits
dose and time dependently and converts the fibrils to
protofibrils [179]. These studies provide evidence for the
role of hyperforin in improving the memory by reduc-
tion of neurotoxic amyloid peptides.
Ginkgo biloba leaves are a common herbal remedy in
traditional Chinese medicine. Extract of Ginkgo biloba
leaves (EGB) demonstrated antidepressant action in
forced swim test and tail suspension test [180]. The
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antidepressant activity have not been determined. It is
likely that terpenoids which represent 6.5% of EGB
[181] play a role in antidepressant action based on the
reported action in the central nervous system [63,182].
Another study demonstrated antidepressant activity of
Ginkgo biloba lipophylic extract in learned helplessness
and behavioral despair animal models[183]. It 6-alkylsa-
licylates have also been implicated as active constituents
related to the antidepressant activity of the Ginkgo
biloba lipophylic extract [183].
Ginkgo biloba leaves exhibits a number of beneficial
effects for AD patients such as cognition and mood
improvements and resolution of mild to moderate
dementia symptoms [184-189]. Although a recent
Ginkgo trial failed to demonstrate prevention of mem-
ory impairment, the authors discuss the possibility that
the extract was given too late to see a preventive effect
[190]. In preclinical studies, Ginkgo biloba extract (EGB
761) blocked the production of amyloid beta peptide
and amyloid precursor protein in aged rodents [191].
EGB 761 also inhibits the aggregation of amyloid pep-
tide and apoptosis by blocking the activation of caspase-
3 in a neuroblastoma cell line [192]. EGB 761 has also
been demonstrated to inhibit amyloid peptide induced
hippocampal cell death [193] and increase the levels of
phosphorylation of CREB that are reduced as a result of
conditioned medium treatment to wild type neuroblas-
toma cells [194]. A study from our laboratory also
demonstrated the neurogenic potential of EGB761 in an
AD mouse model where it induced an increase in cell
proliferation and neuronal precursor cells numbers in
hippocampus [195].
Flavonoids are class of compounds that are derived
from different plants such as tea, Ginkgo biloba and
citrus [196]. Accumulating evidence supports the antide-
pressant activity of flavonoids in depression animal
models [197-199]. Given the fact that depression and
AD share common pathophysiological abnormalities of
CREB- BDNF signaling pathway, citrus and green tea
flavonoids may increase the phosphorylation of CREB
and improve the memory [200,201]. Recently we have
reported that Ginkgo flavonols activate signaling path-
ways, which are heavily implicated in depression includ-
ing the BDNF/pCREB pathway. Additionally, Ginkgo
flavonols also reduced amyloid peptide burden in double
transgenic (TgAPPswe/PSe9) mouse hippocampal neu-
rons [202].
4. Clinical studies of antidepressants on
cognitive function in AD patients
4.1 Antidepressant clinical studies
In general SSRIs have a better tolerability and safety
profile when compared to TCAs. Citalopram is an SSRI
that has been shown to significantly improve the score
of depressed patients in the Hamilton Rating Score
(HAM-D), the Clinical Global Impression Scale, and the
Montgomery Asberg Depression Scale (MADRS) [203].
Citalopram also significantly improves emotional and
cognitive function in a subgroup of patients who suffer
from dementia based on the Gottfries-Brane-Steen
Dementia Rating Scale [203].
The SSRI sertraline was tested in an 8-week trial in 31
female patients diagnosed with late stage AD to deter-
mine its efficacy. Using objective rating scales, including
the Cornell Scale for Depression in Dementia and
others, sertraline and placebo improve ratings similarly
but sertraline treatment showed a better improvement
in “knit brow” facial behavior [204]. “Knit brow” is facial
behavior where the brows are somewhat lowered and
pulled together. It is a robust index of dysphoria in
advanced stage dementia [204]. Another clinical study
with sertraline treatment that lasted 12 weeks involving
22 patients who suffer from major depression and AD
showed that sertaline reduced depressive symptoms sig-
nificantly in comparison to placebo. Interestingly, sertra-
line treated patients do not show any significant change
in daily living activities according to the Psychogeriatric
Dependency Rating Scale in comparison to the placebo
group where there was a significant decline in daily
activities at weeks 9 and 12 [205].
A meta analysis study for the safety and efficacy of
antidepressants in treatment of depression in AD found
that antidepressants are efficacious in treatment of
depression in AD patients and have a similar dropout
rate as placebo [206].
4.2 Combination studies
There are number of reasons for the initiation of combi-
natorial studies that include antidepressants and other
FDA approved drugs for the treatment of AD. First,
impairment in the cholinergic system does not fully
account for age-associated cognitive declines [65,207].
AchEIs also improve behavioral and non-cognitive
aspects [208,209]. Secondly, there is evidence of oxida-
tive stress, neuroinflammation in the postmortem brain
of AD patients. It has been suggested that other neuro-
transmitter systems are involved such as the glutamater-
gic and serotonergic systems [210]. Abnormalities in
monoaminergic systems have been reported in AD
patients [211,212] and AD patients have lower levels of
the neurotransmitter serotonin (5-HT) and its metabo-
lites [213,214]. Accumulating evidence emphasizes the
positive role that serotonin plays in cognitive function
[215]. Improvements in both immediate and delayed
verbal memory after treatment with SSRIs indicate an
enhancement in hippocampal function [62,216]. Also,
the efficacy of memantine for treatment of moderate-to-
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cholinergic impairment do not fully account for age-
associated cognitive decline. These factors provide a
rational argument for the potential beneficial effects for
combinatorial studies between antidepressants and other
FDA approved drugs for the treatment of AD.
To test if the addition of an SSRI (fluoxetine) to an
acetylcholinesterase inhibitor (rivastigmine) treatment
regimen could benefit AD pati e n t s ,ad o u b l eb l i n dp l a -
cebo controlled study was conducted for 12 weeks in
patients with mild to moderate dementia between the
ages of 55-85 years. This study included 122 patients
divided into three treatment groups: placebo, rivastig-
mine only and rivastigmine plus fluoxetine. The results
of this report showed that there were improvements in
cognition and memory in rivastigmine treated and rivas-
tigmine plus fluoxetine treated groups but without a sig-
nificant difference between these two groups.
Interestingly, the rivastigmine plus fluoxetine treatment
group had better performance in daily life activities and
overall function which highlights the benefits that may
be obtained by adding a serotonin regimen to FDA
approved drugs for AD patients [216]. Another study
also reported the beneficial outcome of combining serta-
line (SSRI) with donepzil treatment especially for AD
patients with moderate to severe dementia [217].
The interplay between the cholinergic and the seroto-
nergic systems has an important relevance to AD as
suggested by a number of studies. There is neurochem-
ical and neuroanatomical evidence for the role of choli-
nergic system in modulating the serotonergic one and
the potential synergism between them in improving
memory function [218-223]. A recent study reports that
the acute administration of citalopram reduced glucose
metabolism in the brain while the concomitant adminis-
tration of acetylcholinesterase inhibitor and nicotinic
receptor modulator (galantamine) and citalopram have
increased glucose metabolism. These data suggest a ben-
eficial interplay between the cholinergic and serotoner-
gic systems for AD patients [222].
These clinical studies in addition to preclinical evi-
dence support the positive role of chronic administra-
tion of SSRIs in hindering the disease progression and
improving AD patient clinical outcomes [157,224].
Table 1 Summary of potential targets of antidepressant drugs in relate to AD pathology
Antidepressants Neurogenesis Ab Learning & memory NMDA Receptors
Fluoxetine
(SSRI)
Increase synaptic
density in hippocampus
[75]
Does not interact with
Ab fibrils [159].
Protects hippocampal LTP [100].
Performance improvement in Morris water
maze after chronic treatment [102].
Inhibit NMDA receptor directly
[127].
Amitriptyline
(NSRI)
Does not increase
synapse number but
reduce decline in
synaptic density [76].
Blocks age –induced deterioration of
learning and memory [105].
Tiapentine
(atypical)
Prevents the reduction
of dendrites length as a
result of chronic stress
[77].
Protects hippocampal LTP [99,100]. No
effects on animal performance in Morris
water maze[102] but improve animal
performance is radial maze discrimination
task [104].
TCA Reduce LTP in CA1 pyramidal cells [96,97]. Inhibit NMDA receptor directly
[124,125].
Venlafaxine
(SNRI)
Performance improvement in Morris water
maze after chronic treatment [101,103].
Imipramine
(NSRI)
Increase secreted APP,
reduces intracellular
APP in culture [165].
No effect on animal performance in Morris
water maze [101] and even worsen spatial
working memory in radial arm maze test
[106].
Changes in binding to NMDAR
[118,120]and expression of
NMDAR in brain [116]
Citalopram
(SSRI)
Increase the levels of
secreted APP in the
medium of the treated
neurons [165].
Adaptation of NMDAR complex
[117]. Changes in expression of
NMDAR [116].
Clomipramine
(NSRI)
Chronic administration changes
the regulation of NMDA
receptor control on the release
of dopamine [119].
Milnacipran
(NSRI)
Antagonize NMDA receptor
uncompetitively [126].
Paroxetine
(SSRI)
Reduces levels of Ab
and tau in Tg mice and
cells [157,161-164]
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In this review, we highlighted the high prevalence rate
of comorbidity between AD and depression and sum-
marize different potential targets for antidepressant
drugs that may relate to the AD pathology (see Table
1). Neurodegeneration associated with AD involves dif-
ferent neurotransmitter systems such as the glutamener-
gic, serotonergic, peptidergic and cholinergic systems
[225]. There are myriad of reasons to consider antide-
pressants as an adjunct treatment to AD patients, sev-
eral of which were discussed in this review. Additionally,
we summarized some of the clinical evidence that
demonstrated the beneficial effects of SSRIs in AD
patients either alone or in combination with other FDA
approved acetylcholine esterase inhibitors. The preclini-
cal studies present potential targets that may underlie
antidepressants mechanisms of action in AD pathology
including neurogenic effects, stimulation of learning and
memory, antagonism of NMDA receptors, reduction of
amyloid peptide burden and upregulation of neuro-
trophic factors.
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